1. [The use of Enduracin--a prolonged-action form of nicotinic acid--in correcting atherogenic dyslipidemias].
- Author
-
Oganov RG, Kiseleva NG, Aronov DM, Akhmedzhanov NM, Olfer'ev AM, Kiseleva NS, and Perova NV
- Subjects
- Adult, Aged, Arteriosclerosis blood, Arteriosclerosis etiology, Coronary Disease blood, Coronary Disease complications, Coronary Disease drug therapy, Delayed-Action Preparations, Double-Blind Method, Drug Tolerance, Female, Humans, Hyperlipoproteinemia Type II blood, Hyperlipoproteinemia Type II complications, Lipids blood, Lipoproteins blood, Lipoproteins drug effects, Male, Middle Aged, Time Factors, Arteriosclerosis drug therapy, Hyperlipoproteinemia Type II drug therapy, Hypolipidemic Agents therapeutic use, Niacin therapeutic use
- Abstract
The hypolipidemic effects of induracin, a new long-acting nicotinic acid dosage form based on the waxy matrix, and its tolerance were studied in 31 patients with Types IIa and IIb hyperlipoproteinemias in a 6-month blind crossover study. There were decreases in the levels of total cholesterol by 9-13% and low density lipoprotein cholesterol by 12-22%, an increase in high density lipoprotein cholesterol by 12-15%, and a good dynamics in the ratio of blood lipid-transport proteins--a 12-16% increase to the levels of apoprotein AI to a 29% decrease in those of apoprotein B. The drug is well tolerated by patients and may be recommended for correction of atherogenic dyslipidemias.
- Published
- 1993